Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Louisville, Kentucky Clinical Trials

A listing of Louisville, Kentucky clinical trials actively recruiting patient volunteers.

RESULTS

Found (38) clinical trials

A Multi-centre Study to Assess the Safety Tolerability and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer

The study will be conducted on multiple centers (10) in USA and Spain. The study design allows an exploration of different doses with intensive safety monitoring to ensure the safety of the patients. The two planned combination treatments during Part A of this study are: Part A1: Capivasertib and enzalutamide ...

Phase

5.74 miles

Learn More »

Open-label Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

United Therapeutics Corporation (UTC) is developing a combination drug-device product which is comprised of a dry powder formulation of Treprostinil Inhalation Powder (TreT) and a small, portable, dry powder inhaler. In this Phase 1b safety and tolerability study, patients with PAH on a stable dose of Tyvaso (6 to 12 ...

Phase

5.74 miles

Learn More »

A Safety and Tolerability Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

Phase

6.13 miles

Learn More »

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

A dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of venetoclax, in combination with gilteritinib, in subjects with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have relapsed or progressed after at least 1 prior therapy.

Phase

6.13 miles

Learn More »

Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma

The primary objective is to characterize the safety and tolerability of cemiplimab injected intralesionally in patients with recurrent CSCC. The secondary objectives of this study are: To describe the objective response rate (ORR) in CSCC index lesions following intralesional injections of cemiplimab in patients with recurrent CSCC, according to modified ...

Phase

6.13 miles

Learn More »

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

This is a multicenter, open-label Phase 1b study to assess the safety and efficacy of acalabrutinib when administered concomitantly with bendamustine and rituximab in subjects with treatment naive or relapse refractory mantle cell lymphoma (Part 1), or when administered concomitantly with venetoclax and rituximab in subjects with treatment naive mantle ...

Phase

6.24 miles

Learn More »

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

This study is a dose escalation study to determine a safe and tolerable dose of ASN002 for people with moderate to severe atopic dermatitis. This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and skin biopsies. Subjects will also be assessed for improvement in their ...

Phase

9.51 miles

Learn More »

HEPLISAV-B in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

Eligible participants will receive single doses of HEPLISAV-B at Weeks 0, 4, 8, and 16 and will be followed through Week 68 or end of study (EOS). The study is designed to evaluate the immunogenicity and safety over a 68-week period.

Phase

9.97 miles

Learn More »